SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in Odonate Therapeutics, Inc. ODT shares.
Investors, who purchased shares of Odonate Therapeutics, Inc. ODT prior to December 2017 and continue to hold any of their NASDAQ: ODT shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1 (858) 779-1554.
On September 16, 2020, a lawsuit was filed against Odonate Therapeutics, Inc. ODT over alleged Securities Laws Violations. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that tesetaxel was not as safe or well-tolerated as the Company had led investors to believe, that consequently, tesetaxel's commercial viability as a cancer treatment was overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
On February 16, 2021, an amended complaint was filed and on April 13, a second amended complaint was filed. On May 13, 2021, the defendants filed a motion to dismiss the second amended complaint.
On August 4, the Court denied the defendants' motion to dismiss.
Those who purchased Odonate Therapeutics, Inc. ODT shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.